Mink Therapeutics, Inc. (INKT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Mink Therapeutics, Inc. on June 18, 2025. The company is an emerging growth company incorporated in Delaware with its principal executive offices in New York, New York.
Key Financial Metrics
This filing is a corporate governance report regarding the Annual Meeting and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
A total of 2,793,022 shares (70.41% of eligible shares) were present or represented by proxy, constituting a quorum. Stockholders voted on three proposals:
- Proposal 1 (Director Election): Stockholders elected Jennifer Buell and Ulf Wiinberg as Class I directors for three-year terms.
- Proposal 2 (Option Exchange): Stockholders approved the option exchange proposal.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Breakdown
| Proposal | For | Against | Abstain/Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Proposal 1 (Jennifer Buell) | 2,337,073 | 0 | 31,146 | 424,803 |
| Proposal 1 (Ulf Wiinberg) | 2,312,077 | 0 | 56,142 | 424,803 |
| Proposal 2 (Option Exchange) | 2,269,364 | 97,538 | 1,317 | 424,803 |
| Proposal 3 (Auditor Ratification) | 2,773,188 | 12,846 | 6,988 | 0 |
Guidance, Outlook, and Risks
This filing contains no management commentary on financial guidance, future outlook, specific risks, or contingencies. It strictly reports the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the details of the "Option Exchange Proposal" (Proposal 2) in the Definitive Proxy Statement filed on April 30, 2025, as the 8-K only confirms approval.
- Note that approximately 424,803 shares were broker non-votes on Proposals 1 and 2, indicating brokers did not have discretionary authority to vote on these matters.
- Confirm the terms of the newly elected directors (Jennifer Buell and Ulf Wiinberg) expire at the 2028 Annual Meeting.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K does not include financial metrics.